Trial Investigating the Effect of Semaglutide on Energy Intake, Appetite Sensations, Postprandial Glucose and Triglyceride Metabolism and Gastric Emptying in Obese Subjects Compared With Placebo

Sponsor
Novo Nordisk A/S
Study ID
NCT02079870
Phase
PHASE1
Status
Completed

Conditions

  • Diabetes
  • Metabolism and Nutrition Disorder
  • Obesity

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Accepted

Interventions

  • semaglutide — DRUG
    Solution for subcutaneous (s.c. - under the skin) injection. 0.25 mg semaglutide once weekly for four weeks, 0.5 mg semaglutide once weekly for four weeks followed by 1.0 mg semaglutide once weekly for five weeks
  • placebo — DRUG
    Solution for subcutaneous (s.c. - under the skin) injection

Study Details

This trial is conducted in Europe. The aim of the trial is to investigate the effect of semaglutide on energy intake, appetite sensations, postprandial glucose and triglyceride metabolism and gastric emptying in obese subjects compared with placebo.

Key Dates

Start date
Mar 6, 2014
Status verified
Nov 2017
Primary completion
Jan 7, 2015
Completion
Jan 7, 2015

Study Design

Enrollment
30 participants (actual)
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT

Arms

  • Experimental: Sema
    Two 12-week treatment periods separated by a wash-out period of 5-7 weeks. Finally, a follow-up visit is performed 5-7 weeks after last dosing
  • Placebo Comparator: Placebo

Primary Outcome Measure

Ad libitum energy intake during a lunch meal (following a standardised breakfast meal) [ Time Frame: After 12 weeks of treatment ]

Related Studies